PharmaCyte Biotech, Inc.

Rentabilité sur six mois: -32.21%
Rendement en dividendes: 0%
Secteur: Healthcare

1.01 $

0 $ 0%
1.01 $
2.18 $

paper.min_max_per_year

Calendrier des promotions PharmaCyte Biotech, Inc.

À propos de l'entreprise PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Paramètres de base

IPO date
2010-09-17
ISIN
US71715X2036
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 0.514 10
P/E 60.86 1
Efficacité
Nom Signification Grade
ROA 0.5012 1
ROE 0.5949 1
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 0 10
Debt/Ratio 0 10
Debt/Equity 0.516 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -98.14 0
Rentabilité Ebitda, % -108.78 0
Rentabilité EPS, % -1344.13 0

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.01 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 1.08 $ 0 $ 0 $ -6.48 % 0 % 0 %
common.calendar.number_days.30d 1.05 $ 1.01 $ 1.08 $ -3.81 % 0 % 0 %
common.calendar.number_days.90d 1.23 $ 1.01 $ 1.27 $ -17.89 % 0 % 0 %
common.calendar.number_days.180d 1.49 $ 1.01 $ 1.81 $ -32.21 % 0 % 0 %
common.calendar.number_days.1y 1.53 $ 1.01 $ 2.18 $ -33.99 % 0 % 0 %
common.calendar.number_days.3y 2.6 $ 1.01 $ 3.18 $ -61.15 % 0 % 0 %
common.calendar.number_days.5y 0.0161 $ 0.0042 $ 16.9 $ 6173.29 % 0 % 0 %
common.calendar.number_days.10y 0.0042 $ 0.0042 $ 16.9 $ 24047.62 % 0 % 0 %
common.calendar.number_days.ytd 1.58 $ 1.01 $ 1.81 $ -36.08 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Joshua N. Silverman Interim CEO, Interim President & Interim Chairman 197.92k 1970 (55 années)
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 380k 1958 (67 années)
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer N/A 1957 (68 années)
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant N/A

Informations sur l'entreprise

Adresse: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://pharmacyte.com